Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on targeted radiotherapies, also known as antibody radiation conjugates (ARCs). The company combines monoclonal antibodies with radioactive isotopes to deliver radiation directly to cancer cells while aiming to limit damage to healthy tissue. Its pipeline centers on three areas: the HER3-targeted alpha radiotherapy ATNM-400 for solid tumors, the CD33-targeted agent Actimab-A for AML and myelodysplastic syndrome, and the CD45-targeted conditioning programs Iomab-B and Iomab-ACT for bone marrow transplant and cell-and-gene-therapy conditioning. Actinium is a pioneer in Actinium-225 production and holds an intellectual property portfolio of roughly 250 patents and applications. Investors follow the stock closely because clinical and regulatory milestones, rather than quarterly revenue, tend to define its valuation. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, ATNM delivered a sharp gain. The stock closed at $0.9746 on October 14, 2026, and finished at $1.64 on November 13, 2026, a rise of roughly 68%. The move was punctuated by elevated trading volume in mid-to-late October, when the stock surged from around $1.13 to a peak near $1.60 in a matter of sessions, followed by a more measured climb into November.
The quarterly picture is similarly positive. In early-to-mid August 2026, shares traded in a range of roughly $0.77 to $1.04 before advancing through the autumn. From mid-August levels, the stock has gained more than 50%, reflecting a sustained, catalyst-driven uptrend rather than a single-day spike.
The 30-day rally coincided with a dense calendar of pipeline and corporate announcements. In October 2026, Actinium presented initial first-in-human Phase 1 data for ATNM-400 in metastatic castration-resistant prostate cancer at the European Association of Nuclear Medicine (EANM) congress, with the program also featured at ESMO 2026. Early patients showed no dose-limiting toxicities, and the trial advanced its dose escalation.
Company leadership changes reinforced investor confidence. On October 14–15, 2026, Actinium appointed Matt David, M.D., as Chief Financial Officer, and on October 16, it named radiopharmaceutical industry veteran Sean Maenpaa as Senior Vice President of Business Development. In early November, the company announced a Scientific Advisory Board, the enrollment of patients in its RADIANZ imaging trial intended to demonstrate ATNM-400's pan-cancer potential, and acceptance of an ATNM-400 abstract for the San Antonio Breast Cancer Symposium (SABCS). Actinium also disclosed three ASH 2026 abstracts for Iomab-ACT and long-term Actimab-A data. A reported $35 million licensing transaction contributed to a swing to profitability in the company's latest quarterly results, which beat consensus estimates. Analysts responded favorably, with H.C. Wainwright maintaining a Buy rating and a $4.00 target in November 2026.
Across the quarter, the larger narrative has been Actinium's pivot toward a broader, data-driven pipeline story. After a prior Complete Response Letter for its Iomab-B BLA in 2024, the company has refocused on ATNM-400, Iomab-ACT, and Actimab-A. The quarter featured first-in-human clinical data, new preclinical evidence across lung, breast, colorectal, and ovarian cancer models, and a strengthened leadership and advisory roster. This combination of clinical validation, pan-cancer positioning, and strategic hires supported a sustained repricing of the shares, while elevated trading volume indicated growing institutional and retail interest in the radiopharmaceutical sector.
Looking ahead, investors are likely to monitor Actinium's next earnings report and any guidance on its licensing revenue and cash position. Clinical catalysts include additional ATNM-400 data from the Phase 1 prostate cancer study and the RADIANZ imaging trial, the SABCS presentation in December 2026, and ASH 2026 updates on Iomab-ACT and Actimab-A. Regulatory progress, manufacturing facility readiness, and the company's ability to secure additional partnerships remain important. As with any clinical-stage biopharmaceutical company, trial enrollment, safety signals, and financing needs represent key risks. The information here is presented for educational purposes and does not constitute investment advice.
One resource I turn to regularly is Tickeron’s Trending AI Robots page, which curates top-performing automated trading strategies. It offers perspective on how systematic approaches handle names like ATNM across different timeframes and market conditions, helping me cross-check my own analysis without replacing it.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ATNM as a result. In 75 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ATNM just turned positive on November 10, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in 37 of 49 cases over the following month. The odds of a continued upward trend are 76%.
ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.
Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 168 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 86 of 118 cases where ATNM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 19 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.586). P/E Ratio (4.086) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a biopharmaceutical company developing targeted payload immunotherapeutic for the treatment of advanced cancers
Industry Biotechnology